Lexaria Bioscience (LEXX) FCF Margin Growth (3y) (2020 - 2026)
Lexaria Bioscience (LEXX) FCF Margin Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -1,272.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -2,228.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5,426.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9,545.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4,612.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1,850.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 14,060.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -3,088.00 |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -482,356.00 |
| Aug 31, 2025 | -46,009.00 |
| May 31, 2025 | -79,021.00 |
| Feb 28, 2025 | 330,642.00 |
| Nov 30, 2024 | 721,264.00 |
| Aug 31, 2024 | 128,210.00 |
| May 31, 2024 | -94,037.00 |
| Feb 29, 2024 | -9,510.00 |
| Nov 30, 2023 | -50,730.00 |
| Aug 31, 2023 | -427,615.00 |
| May 31, 2023 | -45,753.00 |
| Feb 28, 2023 | -419,214.00 |
| Nov 30, 2022 | 407,728.00 |
| Aug 31, 2022 | -46,226.00 |
| May 31, 2022 | 89,443.00 |
| Feb 28, 2022 | 183,685.00 |
| Nov 30, 2021 | -561,421.00 |
| Aug 31, 2021 | -271,654.00 |
| May 31, 2021 | -16,802.00 |
| Feb 28, 2021 | 1,721.00 |